The Potential of Gallic Acid as a Radiosensitizer on Human Prostate Cancer: A Systematic Review of Preclinical Studies
Malaysian Journal of Medicine and Health Sciences
; : 246-254, 2021.
Article
in En
| WPRIM
| ID: wpr-978594
Responsible library:
WPRO
ABSTRACT
@#Prostate adenocarcinoma accounts for majority of prostate cancer cases, and it was found to be highly radioresistant. Gallic acid is a phenolic acid naturally occurring in many plants, reported to exhibit biological activities in eliminating cancer cell lines and xenografts. The purpose of this study is to review gallic acid as a potential radiosensitizer agent in prostate cancer treatment. Article search was conducted in PubMed, EBSCO, and Scopus. 11 studies using different cell lines including DU145, PC-3, LNCaP, and 22Rv1 xenograft of human prostate cancer were reviewed in this paper. Gallic acid acts as a radiosensitizer mainly by increasing caspase-3 and caspase-9 activation resulting in apoptosis, while also reducing intracellular CDKs, cyclins, and cdc25 phosphatases ultimately causing G2-M cell cycle arrest. Gallic acid has a potential to be a new radiosensitizer compound in prostate cancer treatment. Additional clinical studies using gallic acid derivatives with lower hydrophilicity are needed.
Search on Google
Index:
WPRIM
Type of study:
Systematic_reviews
Language:
En
Journal:
Malaysian Journal of Medicine and Health Sciences
Year:
2021
Type:
Article